Pharming Group (NASDAQ:PHAR – Get Rating) shares saw unusually-strong trading volume on Friday . Approximately 400 shares traded hands during trading, a decline of 95% from the previous session's volume of 8,111 shares.The stock last traded at $11.93 and had previously closed at $11.75.

Analyst Upgrades and Downgrades

Separately, TheStreet raised Pharming Group from a "d+" rating to a "c" rating in a research report on Monday, August 15th.

Pharming Group Trading Up 0.1 %

The business has a 50-day moving average of $10.59 and a 200-day moving average of $9.59. The stock has a market cap of $767.69 million, a price-to-earnings ratio of 28.68 and a beta of -0.30. The company has a quick ratio of 4.68, a current ratio of 5.40 and a debt-to-equity ratio of 0.60.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.

See Also

• Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
• MarketBeat: Week in Review 11/21 – 11/25
• Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
• Three CBD Stocks to Dominate a Budding Industry
• Is the 60/40 Portfolio Mix Still in Vogue?
• Institutional Support for Analog Devices Remains High

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.